PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pritelivir→

Pritelivir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
348086-71-5
Molecular formula
C18H18N4O3S2
Molecular weight
402.49 g/mol
Drug class
Investigational antiviralherpes simplex virus (HSV) helicase-primase inhibitor
Mechanism of action
Inhibits the HSV helicase-primase complex, preventing viral DNA unwinding and replication. This mechanism is distinct from nucleoside analogues such as acyclovir.
Indications / reported uses
  • Investigational oral treatment studied for acyclovir-resistant or acyclovir-refractory HSV infection, including in immunocompromised adults; pritelivir should not be represented as an approved routine therapy.

Sources: https://pubmed.ncbi.nlm.nih.gov/42751311/ · https://clinicaltrials.gov/search?term=pritelivir · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Pritelivir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pritelivir Permitted Daily Exposure (PDE) report (the Pritelivir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pritelivir Occupational Exposure Limit (OEL) report (the Pritelivir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.